275 related articles for article (PubMed ID: 15854349)
1. [Correlation of benign prostatic hyperplasia with hyperlipemia].
Li PJ; Zhang XH; Guo LJ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):387-9. PubMed ID: 15854349
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of serum prostate specific antigen, the volume and the intravesical prostatic protrusion for diagnosing bladder outlet obstruction in patients with benign prostate hyperplasia].
Bantis A; Zissimopoulos A; Kalaytzis C; Giannakopoulos S; Sountoulides P; Agelonidou E; Voudalikakis C; Touloupidis S
Hell J Nucl Med; 2007; 10(2):138-43. PubMed ID: 17684595
[TBL] [Abstract][Full Text] [Related]
3. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
Tsukamoto T; Masumori N; Rahman M; Crane MM
Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
[TBL] [Abstract][Full Text] [Related]
4. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
[TBL] [Abstract][Full Text] [Related]
5. [Association study between benign prostatic hyperplasia and primary hypertension].
Guo LJ; Zhang XH; Li PJ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Jan; 43(2):108-11. PubMed ID: 15771818
[TBL] [Abstract][Full Text] [Related]
6. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
7. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
Trachtenberg J
BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
[TBL] [Abstract][Full Text] [Related]
10. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
Xu J; Qian WQ; Song JD
Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
12. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia.
Roehrborn CG
Int J Impot Res; 2008 Dec; 20 Suppl 3():S19-26. PubMed ID: 19002120
[TBL] [Abstract][Full Text] [Related]
13. [Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens].
Zhang YG; Wang JY; Liu M; Wan B; Wei D; Deng SM; Xu J; Wu JY; Chu X; Zeng P
Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(24):1690-2. PubMed ID: 19024540
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of prostatic-specific antigen levels in patients with benign prostatic hyperplasia complicated by low urinary tract syndrome].
Zhu YJ; Ye M; Wang WM; Shen HB; Chen JH; Chen F
Zhonghua Nan Ke Xue; 2006 Feb; 12(2):156-8. PubMed ID: 16519156
[TBL] [Abstract][Full Text] [Related]
15. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
[TBL] [Abstract][Full Text] [Related]
16. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
[TBL] [Abstract][Full Text] [Related]
17. [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period].
Zhang YG; Wang JY; Liu M; Xu J; Wu JY; Xin Y; Wan B; Wei D; Zhu SC; Zeng P
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):611-3. PubMed ID: 19040049
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
[TBL] [Abstract][Full Text] [Related]
20. Definition of at-risk patients: dynamic variables.
Emberton M
BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
